Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREBYX versus TRIDIONE.
CEREBYX vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category C
Category C
Anticonvulsant
Anticonvulsant